je.st
news
Tag: combination
Study: Housing developments near drying forests a deadly combination in the West
2014-03-08 18:52:00| Climate Ark Climate Change & Global Warming Newsfeed
Washington Post: As the climate warms, forest fires in the West increasingly will feast on acres of dry brush, growing into giants. In a cycle that will become routine, homeowners will flee, while firefighters will rush toward their houses -- and away from areas where they could be putting out wildfires. Bigger, unwiedly burns -- megafires -- are becoming the new normal, according to a new report, which points to several reasons: States such as California are getting parched more frequently by drought; housing...
Tags: the
west
study
combination
Combination Inspector - Opens February 24, 2014
2014-02-24 19:14:12| PortlandOnline
PDF Document, 141kbCategory: Career Opportunities
Tags: february
combination
opens
inspector
Frost & Sullivan: RFaxis' Single-Chip/Single-Die RF Front-End Solutions Offer The Best Possible Combination Of Cost Effectiveness And Performance
2014-02-21 08:33:35| rfglobalnet News Articles
Based on its recent analysis of the market for radio frequency front-end module (RF FEM) solution for wireless communication, Frost & Sullivan recognizes RFaxis, Inc. with the 2014 North American Frost & Sullivan Award for Technology Innovation Leadership.
Tags: offer
cost
performance
solutions
Combination Products: Clinical Benefits, Regulatory Issues & Manufacturing Challenges
2014-02-10 15:48:04| drugdiscoveryonline News Articles
Dates:April 3 (Part I) and April 10 (Part II), 2014 Time: 1pm - 2:30pm EST, each day Duration: 90 Minutes - Online Price: $549 - Introductory Rate
Tags: products
issues
benefits
combination
Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475
2014-02-05 12:40:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Merck Also to Initiate Phase I Signal Finding Study with MK-3475 in 20 New Cancer Types WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today it has signed three separate clinical collaboration agreements, through subsidiaries, with Amgen Inc., Incyte Corporation and Pfizer Inc. to evaluate novel combination regimens with MK-3475, Mercks investigational anti-PD-1 immunotherapy. The financial terms of the agreements were not disclosed. Language: English Contact: MerckMedia:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
combination
strategic
evaluate
Sites : [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] next »